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Vessel wall remodeling is an integral pathological process central to cardiovascular diseases including atherogen-
esis, plaque rupture, and neointimal hyperplasia–associated 
vein graft failure and in-stent restenosis.1,2 Resident vascular 
smooth muscle cells (VSMCs) are typically quiescent and 
contractile in the normal physiological state. However, fol-
lowing pathological or iatrogenic vascular injury, the release 
of cytokines and growth factors from VSMCs, aggregated 
platelets, and inflammatory cells on the damaged intimal 
surface leads to phenotypic switching of VSMCs and the 
adoption of a more synthetic, pro-proliferative, and promi-
gratory state.3 In the setting of the pathological injury of ath-
erosclerosis, VSMCs not only contribute to the atherogenic 
process itself but can also engender plaque stabilization 
through the generation of a thick-capped fibroatheroma. For 
acute iatrogenic vascular injury, overexuberant proliferation 
of VSMC subpopulations promotes neointimal hyperplasia 
leading to luminal narrowing such as seen in vein graft failure 
or in-stent restenosis.4 Phenotypic switching of VSMCs and 
release of cytokines and growth factors are therefore criti-
cal in vascular disease, and understanding the mechanisms 
involved is critical to gain insights into the pathology and 
identify new opportunities for therapies.
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The highly conserved interleukin-1α (IL1α) and platelet-
derived growth factor (PDGF) pathways play prominent roles 
in VSMC-associated pathologies.1,5 IL1α is a central media-
tor in the cytokine cascade and a potent activator of vascu-
lar cytokine production. Furthermore, previous studies have 
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demonstrated that ligation injury results in reduced neointi-
mal formation in IL1 receptor knockout mice.6 Downstream 
mediators include the signaling molecules MEKK1 and p38 
and the transcription factor NF-κB that activate mediators 
of inflammation and cellular migration.7 PDGF is a potent 
mitogen and chemoattractant, and expression is increased 
following vascular injury.8 Conversely, a reduction in PDGF 
expression reduces intimal thickening and cellular content of 
the neointima.9 Activation of both IL1α and PDGF signaling 
pathways simultaneously can activate common downstream 
targets leading to additive or synergistic effects. This includes 
activation of NF-κB leading to the upregulation of metallo-
proteinase 3 and 9,10 genes critical in the development of vas-
culoproliferative pathologies.
Over the past decade, there has been substantial interest 
in determining the complex interactions between hierarchical 
levels of gene regulation. Up to 90% of the human genome 
is transcribed at different developmental stages and only ≈2% 
of RNA molecules are translated into protein.11 The functional 
complexity of organisms therefore appears to be reliant on 
noncoding RNA molecules. Noncoding RNAs are subdivided 
into several classes, including microRNA (miRNA) and long 
noncoding RNA (lncRNA). miRNAs are abundantly expressed 
in vascular tissues and play an important role in vascular 
pathology. Interestingly, recent studies have demonstrated that 
miRNAs are capable of being released into the blood from 
injured cells. These miRNAs are relatively stable and have 
been reported as biomarkers for several disease states, includ-
ing myocardial infarction12 and heart failure.13,14 Although the 
role of miRNAs is reasonably established in the setting of car-
diovascular pathology, relatively little is known about the role 
of lncRNAs. lncRNAs are capable of regulating target DNA, 
RNA, and protein at the pre- and posttranscriptional level. It 
is becoming clear that lncRNAs play a pivotal role in cellular 
physiology and pathology via localization in subpopulations 
of cells and through highly controlled temporal expression.15 
However, detailed insights into their regulation and biologi-
cal roles are only beginning to emerge. In the vascular setting, 
SENCR and MALAT1 have been implicated in the control of 
vascular cell migration and endothelial cell sprouting, respec-
tively.16,17 Interestingly, SENCR is implicated in phenotypic 
switching of VSMCs to a more promigratory phenotype 
because knockdown of this lncRNA downregulates contractile 
genes.17 A greater understanding of lncRNAs in quiescent and 
proliferative VSMCs may provide valuable insight into the spe-
cific roles of lncRNAs in response to pathological processes.
Methods
Human Tissue Samples
Surplus human saphenous vein tissue was obtained from patients 
undergoing coronary artery bypass grafting. Carotid plaques were 
obtained from patients undergoing endarterectomy following an acute 
and symptomatic neurovascular event. Human plasma samples were 
used from a previously published study: Carotid Ultrasound and Risk 
of Vascular disease in Europeans and South Asians (CURVES).2 All 
patients gave their written, informed consent. All procedures had local 
ethical approval (06/S0703/110, 12/WS/0227, 09/S0703/118, and 
12/NW/0036). All studies were approved by East and West Scotland 
Research Ethics Committees, and all experiments were conducted 
according to the principles expressed in the Declaration of Helsinki.
Tissue and Cell Culture
All cells were maintained at 37°C in a humidified atmosphere con-
taining 5% CO2. Primary human saphenous vein–derived endothelial 
cells (HSVECs) were isolated by a modified version of the protocol 
described by Jaffe and colleagues18 and maintained in large-vessel 
endothelial cell culture medium supplemented with 20% fetal calf 
serum (Life Technologies, Paisley, UK). Primary human saphenous 
vein–derived smooth muscle cells (HSVSMCs) were isolated from 
medial explants19 and maintained in Smooth Muscle Cell Growth 
Medium 2 (PromoCell, Heidelberg, Germany) with supplements. 
Human coronary artery VSMCs were purchased from Lonza (Basel, 
Switzerland) and maintained in VSMC media as above.
Sample Preparation for RNA-seq Library 
Construction and Analysis
HSVSMCs were plated, quiesced in medium containing 0.2% fetal 
calf serum for 48 hours before the stimulation with 10 ng/mL IL1α, 
20 ng/mL PDGF (R&D Systems) or a combination of both for 72 
hours. Total RNA was processed through miRNeasy kit (Qiagen, 
Hilden, Germany) following the manufacturer’s instructions, 
treated with DNase 1 (amplification grade; Sigma, St. Louis, MO) 
to eliminate genomic DNA contamination and quantified by using a 
NanoDrop ND-1000 Spectrophotometer (Nano-Drop Technologies, 
Wilmington, DE). Following bioanalyzer quality control for RNA 
integrity number values >8, RNA sequencing (RNA-seq) was per-
formed on ribosomal-depleted RNA using an Illumina Hiseq plat-
form by Beckman Coulter Genomics. Paired-end sequencing was 
performed with a read depth of 70 million (n=4/group). RNA-
seq reads were processed and trimmed to ensure quality, adapter 
sequences were removed using Flexbar20 and mapped to the Ensembl 
annotation of GRCh37.75 using the TopHat2 version 2.0.9.21 The 
transcriptome was assembled from the aligned reads and quantified 
using Cufflinks version 2.2.1.22 The differential expression levels 
between the groups were assessed using Cuffdiff version 2.2.1.23 The 
data set is deposited in the Gene Expression Omnibus (GEO) reposi-
tory, study number GSE69637. The biotype of each transcript was 
annotated according to the Ensembl database. Normalization and sta-
tistical analysis of differentially expressed transcripts were performed 
by using edgeR and data filtered to find transcripts that were differ-
entially expressed (P<0.01) between 0.2% media and each treatment 
group. Differentially expressed lncRNAs, between control and both 
IL1α/PDGF treatments, were explored by using more stringent crite-
ria (P<0.01, false discover rate [FDR] <0.01, log fold change>2) and 
filtered according to transcript abundance (fragments per kilobase of 
exon per million fragments mapped [FPKM]>1 in at least 1 group). 
Data outputs such as pie charts and heatmaps were generated using R. 
Ingenuity pathway analysis was performed by using protein-coding 
genes differentially expressed (FDR<0.01) from Edge R analysis.
Assessment of RNA Secretion From HSVSMC
RNA extraction on conditioned HSVSMC media was performed 
by using a standard volume (2 mL). The conditioned media was 
first centrifuged (10 minutes; 2000g; 4°C) to remove all cells 
and debris. After addition of 1.4 mL of QIAzol (Qiagen), 3 µL of 
Caenorhabditis elegans total RNA at 25 ng/µL was added to each 
sample. Following 5-minute incubation at room temperature, 140 
µL of chloroform was added and samples centrifuged (15 min-
utes; 15 000g; 4°C). The clear upper aqueous phase was used to 
isolate RNA by using the miRNEasy mini kit (Qiagen) as previ-
ously described with alteration of the final wash step (75% ethanol 
in diethylpyrocarbonate water). Different quantities of total RNA 
were spiked and a dose-response effect was observed (Figure IA in 
the online-only Data Supplement). The quality of the amplicon was 
assessed via analysis of melting curves (Figure IB in the online-
only Data Supplement) and subsequent visualization on agarose 
gel (Figure IC in the online-only Data Supplement). This showed a 
unique amplification product corresponding to the cDNA fragment 
of ama-1. Because of the correlation observed between the quan-
tity of spike-in and ama-1 expression (Figure ID in the online-only 
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Data Supplement), we used 75 ng in all subsequent extractions. This 
amount allowed reproducibility of our method, with the Ct values 
of ama-1 being 29.4±0.3 across 5 separate extractions in noncondi-
tioned media (Figure IE in the online-only Data Supplement).
Gene Expression qRT-PCR
For gene expression analysis, cDNA for mRNA analysis was obtained 
from total RNA using the Multiscribe Reverse Transcriptase (Life 
Technologies, Paisley, UK). Quantitative real-time polymerase chain 
reaction (qRT-PCR) was performed using Power SYBR green (Life 
Technologies) with custom PCR primers (Eurofins MWG, Ebersberg, 
Germany), the specificity of these primers was confirmed by perform-
ing a melting curve and running their PCR produce on a gel (Table I 
in the online-only Data Supplement – primer sequences). Ubiquitin 
C was selected as housekeeping gene because of its stability across 
all groups studied. Fold changes were calculated by using the 2-ΔΔCt 
method.23
Statistical Analysis
Statistical analysis was performed according to figure legends. Data 
in graphs are shown on relative expression scales as referenced by 
Livak and Schmittgen.24 Data are given as both mean±standard 
deviation (shown as bars and whiskers) and also as the individual 
points to clearly represent the data. Note that as the relative expres-
sion scale is inherently skewed; the bars indicate the geometric 
mean of the relative expression fold change, and the standard devia-
tion whiskers denote the relative expression fold change equivalent 
to an increase of 1 standard deviation above the mean on the log-
transformed scale. All statistical analysis is performed on the dCt 
scale (a logarithmic transformation of the data shown on the rela-
tive quantification in the plots).24 No evidence of unequal variances 
across groups was found for any of analyses of the dCt scale data 
using the Levene test on Minitab version 17 before statistical analy-
sis. Comparisons between 2 groups were analyzed using 2-tailed 
unpaired or paired Student t test. One-way analysis of variance with 
Tukey post hoc or 1-way analysis of variance multiple-comparisons 
test for pooled samples, via Graph Pad Prism version 5.0, was 
used for comparisons among ≥3 groups. Statistical significance is 
denoted by a P value of <0.05.
Results
Induction of Inflammatory and Cell Cycle Pathways 
by IL1α and PDGF
We sought to identify lncRNAs that are regulated during 
the induction of proliferative and inflammatory pathways 
in HSVSMCs. RNAs were identified by using RNA-seq of 
HSVSMC treated for 72 hours (Figure 1A). Activation of the 
IL1α and PDGF signaling pathways was confirmed by the 
presence of the inflammatory miRNA miR-146a (Figure1B) 
and induction of VSMC proliferation (Figure 1C). The 
RNA sequencing obtained an average of 70 million reads 
per sample, with 93.5% aligning to the GRCh37 genome 
reference files. The majority of reads, under all conditions, 
corresponded to mRNA (49.6±0.48%; Figure 1D and Figure 
IIA in the online-only Data Supplement). To identify the 
biological function, networks, and canonical pathways that 
were affected by VSMC stimulation, we performed inge-
nuity pathway analysis after RNA-seq analysis. Ingenuity 
pathway analysis confirmed that the mRNAs with altered 
expression following IL1α treatment were significantly 
enriched in pathways related to cellular movement and 
inflammatory disease (Table II in the online-only Data 
Supplement), whereas PDGF stimulation led to the marked 
enrichment in cell cycle pathways (Table III in the online-
only Data Supplement). Interestingly, costimulation led to 
enrichment in cell cycle and cardiovascular development 
pathways (Table IV in the online-only Data Supplement). 
Further analysis of differentially expressed mRNAs with a 
stringent cutoff of FDR<0.01 identified 518 protein-coding 
genes altered following IL1α treatment and 540 following 
PDGF treatment. Notably, dual stimulation altered 1133 
known protein-coding genes with 480 uniquely associated 
with dual stimulation and not affected by IL1α or PDGF 
treatment alone (Figure 1E and Figure IIB in the online-
only Data Supplement).
Identification of Differentially Expressed lncRNAs 
in HSVSMCs Treated With IL1α and PDGF
We next assessed whether lncRNAs were dynamically 
regulated by growth factor and cytokine stimulation. 
Approximately 33% of reads in each condition aligned to 
known or predicted lncRNAs (Figure IIIA in the online-only 
Data Supplement). Differential expression analysis con-
firmed substantial differences in lncRNA expression between 
control and stimulated cells. Using the stringent criteria FDR 
≤0.01 and log2 fold change ≥2, to declare significance and 
FPKM >1, to confirm quantifiable expression we identified 
224, 215, and 369 differentially expressed lncRNAs follow-
ing IL1α, PDGF, or dual stimulation, respectively (Figure 
IIIA in the online-only Data Supplement). Because lncRNAs 
can typically contain multiple splice variants, the numbers 
quoted refer to a single consensus gene model and there-
fore do not reflect the multiple transcripts of each lncRNA. 
To determine whether specific biotypes of lncRNA were 
enriched following HSVSMC stimulation, those differen-
tially expressed were further subdivided according to bio-
type in the Ensembl database. LncRNA biotypes are based on 
their relative orientation to protein-coding genes; intervening 
lncRNA (lincRNA), antisense, overlapping and processed 
transcripts. With the use of control and dual stimulation as an 
example, the distribution of different lncRNA biotypes was 
as follows: intervening (45.5%), antisense (45.3%), overlap-
ping (1.4%), and processed transcripts (7.9%; Figure IIIB 
in the online-only Data Supplement). Focusing on lincRNA, 
the candidates (control versus IL1α and PDGF, FDR<0.01, 
log fold change <2, FPKM>1) were ranked according to 
their FPKM and level of upregulation/downregulation 
(Figure 2A, Figure IV in the online-only Data Supplement 
for heat map of all conditions). A subset of the most dif-
ferentially expressed transcripts was identified and validated 
by qRT-PCR (RP11-91k9.1, RP11-94a24.1, RP11-709B3.2, 
RP11-760H22.2, and AC018647.3; Figure 2B, chromosomal 
locations in Table I in the online-only Data Supplement). 
This was consistent with the RNA-seq results, showing 
RP11-94a24.1 and RP11-91k9.1 upregulated 20.2±30– and 
45±26.4–fold, respectively, following costimulation and 
lncRNAs RP11-709B3.2, RP11-760H22.2, and AC018647.3 
being downregulated 16-, 28-, and 1209-fold, respectively 
(Figure 3A; relative quantification=0.06±0.04, 0.035±0.01, 
and 0.0008±0.001, respectively). The dissociation curves 
and gel products of each primer set are shown in Figure V in 
the online-only Data Supplement.
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Vascular Enriched Expression of RP11-94a24.1 
The expression of each lncRNA was quantified in a range 
of 10 normal human tissues including specimens derived 
from brain, gastrointestinal, reproductive, and endocrine sys-
tems. In general, lncRNAs were expressed at relatively low 
levels across the tissue panel. However, we observed that 
RP11-94a24.1 was expressed highest in the heart, whereas 
RP11-91K9.1 and AC018647.3 showed preferential expres-
sion within the liver and brain, respectively. RP11-709B3.2 
and RP11-760H22.2 displayed highest expression in the 
spleen and thyroid, respectively (Figure VIA in the online-
only Data Supplement). We next examined the expression of 
each lncRNA in primary HSVECs, HSVSMCs, and human 
coronary artery SMCs. All lncRNAs had higher expres-
sion in VSMCs of either venous or arterial lineage than in 
endothelial cells, suggesting VSMC enrichment (Figure 
VIB in the online-only Data Supplement). We also assessed 
whether the expression of these lncRNAs could be modu-
lated by IL1α and PDGF in HSVECs as had been found 
in the HSVSMCs. Notably, subsequent downregulation of 
Figure 1. RNA sequencing shows IL1α and PDGF induction of inflammatory and cell cycle pathways. A, Study design for determination 
of the transcriptome in quiescent and stimulated HSVSMCs. HSVSMCs were treated for 72 hours, RNA quality was assessed and 
subjected to RNA-seq following the Tuxedo pipeline for analysis. B, Known inflammatory microRNA, miR146a, is upregulated by IL1α 
(n=4). **P<0.01 vs 0.2% condition. Multiple comparison 1-way ANOVA. C, BrdU incorporation as an indirect marker of proliferation 
was assessed in all patients (n=3). **P<0.01 vs 0.2% condition. D, Biotype distribution of all transcripts identified by RNA-seq analysis 
generated from HSVSMCs treated with IL1α and PDGF, cutoff at FPKM>0.1 E, Venn diagram indicating overlap of protein-coding 
genes with altered expression (analyzed using EdgeR, FDR<0.01) across each treatment. ANOVA indicates analysis of variance; BrdU, 
bromodeoxyuridine; FC, fold change; FDR, false discovery rate; FPKM, fragments per kilobase of exon per million fragments mapped; 
HSVSMC, human saphenous vein–derived smooth muscle cell; IL1α, interleukin-1α; lncRNA, long noncoding RNA; miR, microRNA; 
miscRNA, miscellaneous RNA; miRNA, microRNA; PDGF, platelet-derived growth factor; and UBC, ubiquitin C.
B CA
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RP11-709B3.2, RP11-760H22.2, and AC018647.3 was not 
observed in HSVECs as was the case in HSVSMCs (data 
not shown). Stimulation of HSVECs produced a significant 
3.8±0.7– and 8.7±2.1–fold upregulation of RP11-91K9.1 fol-
lowing IL1α and IL1α/PDGF treatment, respectively (Figure 
3B). However, stimulation had no effect on RP11-94a24.1 
expression (Figure 3B), indicating selective regulation in 
HSVSMCs. Because of the expression of RP11-94a24.1 
in HSVSMCs and its cell-specific induction in response to 
pathological mediators of vascular injury, we focused further 
studies on RP11-94a24.1. We termed this lncRNA, smooth 
muscle–induced lncRNA enhances replication (SMILR). 
SMILR expression was assessed through the use of 3 indepen-
dent primer sets targeting differential exons of the lncRNA. 
qRT-PCR revealed similar Ct and fold changes among the 
3 sets, further confirming our previous data (Figure VII in 
the online-only Data Supplement). The longest open reading 
frame within SMILR is 57 amino acids. Analysis of this open 
reading frame using the Coding Potential Calculator (http://
cpc.cbi.pku.edu.cn) did not reveal any similarity to known 
protein-coding sequences suggesting that this RNA has no 
protein-coding potential (data not shown).
IL1α/PDGF Treatment Induces the Expression of 
SMILR in a Time-Dependent Manner 
To investigate the longitudinal regulation of SMILR, we stim-
ulated HSVSMCs with PDGF, IL1α, or a combination of both 
(1.5, 4, 24, 48, and 72 hours). We found significant upregula-
tion of SMILR in response to PDGF as early as 4 hours after 
stimulation. By 24 hours, SMILR expression was increased 
by treatment with PDGF or IL1α, and both together, as well 
(Figure VIII in the online-only Data Supplement). The com-
bination of PDGF and IL1α induced a synergistic increase in 
SMILR expression at 72 hours.
Figure 2. Identification of differentially expressed lncRNAs in HSVSMCs treated with IL1α and PDGF. A, Heatmaps showing order of 
differentially expressed transcripts within the 4 patient samples before and after IL1α/PDGF treatment. lncRNA selected for validation 
marked by *. B, Heatmap representing the fold change of the 5 lncRNAs selected for validation. Heatmaps represent data from RNA-seq 
pipeline. HSVSMC indicates human saphenous vein–derived smooth muscle cell; IL1α, interleukin-1α; lncRNA, long noncoding RNA; and 
PDGF, platelet-derived growth factor.
A
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Cellular Localization of SMILR in HSVSM Cells
Rapid amplification of cDNA ends25 was used to design spe-
cific RNA fluorescent in situ hybridization (FISH) probes. RNA 
FISH highlighted a SMILR isoform, consisting of an additional 
6 bp at the 5′ end and 316 bp at the 3′ end (Figure IXA and 
IXB in the online-only Data Supplement). Rapid amplification 
of cDNA ends data are supported by the raw RNA-seq files 
(Figure XA through XC in the online-only Data Supplement).
We performed RNA FISH to provide visuospatial infor-
mation as to the location of SMILR within HSVMSCs. 
Negative control samples showed no fluorescent signal, 
whereas SNORD3 fluorescent activity confirmed the nuclear 
Figure 3. Treatment with IL1α and PDGF significantly altered lncRNA expression and showed distinct expression within vascular cell 
types. A, Graphs indicate fold change of lncRNA from RNA-seq data and subsequent validation by qRT-PCR (n=4). *P<0.05, **P<0.01, 
***P<0.001 vs 0.2% condition. B, Basal and stimulated expression of lncRNAs 2 and 7 within HSVEC and HSVSMC (n=4 for SMC and 
n=3 for EC; *P<0.05, **P<0.01, ***P<0.001 vs 0.2% in each specific cell type). EC indicates endothelial cell; HSVEC, human saphenous 
vein–derived endothelial cell; HSVSMC, human saphenous vein–derived smooth muscle cell; IL1α, interleukin-1α; lncRNA, long 
noncoding RNA; PDGF, platelet-derived growth factor; qRT-PCR, quantitative real-time polymerase chain reaction; SMC, smooth muscle 
cell; and UBC, ubiquitin U.
A B
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permeabilization of cells (Figure 4A). In the absence of growth 
factor and cytokine stimulation, HSVSMCs typically exhib-
ited between 0 and 3 positive fluorescent signals correspond-
ing to SMILR localization (Figure 4A). IL1α/PDGF treatment 
induced a marked increase in fluorescent signal within the 
nucleus and cytoplasm of HSVSMCs. Further specificity of 
the FISH probes was confirmed through the use of cells treated 
with either lentivirus containing SMILR or small interfering 
RNA (siRNA)–targeting SMILR. In each case, an increase 
and decrease in SMILR transcripts was observed (Figure 4A). 
Quantification of FISH samples is provided in Figure 4B. In the 
absence of stimulation, 2±3.6 SMILR molecules were observed. 
Following stimulation, 25±5 individual SMILR molecules were 
observed within the nucleus and cytoplasm (Figure 4B).
Identifying Upstream Mediators of SMILR 
Expression in HSVSMCs
It is well established that IL1α and PDGF work through distinct 
pathways leading to vascular cell activation. To assess the func-
tional consequences of inhibition of these pathways on SMILR 
expression, selective pharmacological inhibitors AZD6244 
(MEKK1) and SB 203580 (p38) were used (Figure 5A). 
Following 60 minutes of pretreatment with inhibitors, VSMCs 
were stimulated with IL1α/PDGF, and the expression of SMILR 
was determined at 24 hours. Pretreatment with AZD6244 (5, 10, 
or 15 µmol/L) prevented the induction of SMILR in response to 
PDGF and IL1α (Figure 5B), whereas inhibition of p38 with 
SB203580 induced a dose-dependent reduction in SMILR 
expression in response to PDGF and IL1α (Figure 5C).
Figure 4. Localization of SMILR. A, RNA FISH analysis of SMILR, cytoplasmic UBC mRNA, and nuclear SNORD3 RNA in HSVSMC. 
Magnification ×630 for all panels. UBC and SNORD3 used for confirmation of cellular compartments. B, Quantification of lncRNA 
molecules per cell in indicated conditions. More than 5 images were selected at random from each condition, and at least 4 cells were 
counted in each image. DAPI indicates 4,6-diamidino-2-phenylindole-2-HCl; FISH, fluorescent in situ hybridization; HSVSMC, human 
saphenous vein–derived smooth muscle cell; IL1α, interleukin-1α; lncRNA, long noncoding RNA; LV, lentivirus; PDGF, platelet-derived 
growth factor; si, small interfering; UBC, ubiquitin U.
A
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IL1α/PDGF Treatment Induces the Release of 
SMILR Into Conditioned Media
miRNAs have been reported to be secreted from cells as 
a means of cell-to-cell communication.26 To investigate 
whether HSVSMCs release SMILR as an indication of 
expression, we modified a method commonly used to evalu-
ate miRNA expression.27 Because no endogenous control was 
stably expressed across all conditions in this study, an exog-
enous control was added to monitor extraction efficiency and 
to normalize data. Consequently, total RNA from C elegans 
was used as a spike-in, and ama-1 encoding polymerase II 
was chosen as a control for its high constitutive expression 
(see Methods). Interestingly, SMILR was detected at low lev-
els in media from quiesced VSMCs and those stimulated by 
Figure 5. Functional regulation of SMILR. A, Schematic diagram showing specific sites of inhibition. HSVSMCs were pretreated for 60 
minutes with the indicated concentration of the inhibitors. Following exposure to vehicle or 10 ng/mL IL1 or 20 nmol/L PDGF for 24 hours, 
expression of SMILR was determined by qRT-PCR. B, SMILR expression following MEKK1 inhibition. ***P<0.01 vs 0.2% media, ### 
P<0.001 vs IL1/PDGF treatment. Repeated-measures ANOVA (n=3). C, SMILR expression following p38 inhibition. Repeated-measures 
ANOVA. ***P<0.01 vs 0.2% media, ### P<0.001 vs IL1/PDGF treatment alone (n=3). D, SMILR expression in conditioned media from 
HSVSMCs cultured in 0.2%, IL1 or PDGF conditions. Unpaired t test. *P<0.05 vs 0.2% (n=4). E, Confirmation of the effect of siRNA 
targeting SMILR in HSVSMCs by using qRT-PCR (n=3). One-way ANOVA ***P<0.001 vs 0.2% control. ### P<0.001 vs IL1 + PDGF 
treatment. F, IL1/PDGF induced proliferation classed as 100% for analysis across patient samples, knockdown of SMILR inhibits EdU 
incorporation in HSVSMCs (n=3) One-way ANOVA vs Si control. ## P<0.01. G, qRT-PCR analysis of SMILR expression following infection 
with either an empty lentivirus (LV-E) or lentivirus containing SMILR sequence (LV-S) at an MOI of 25 (n=3) and MOI 50 (n=3) ***P<0.001 vs 
relevant empty control assessed via multiple-comparison ANOVA. ANOVA indicates analysis of variance; EdU, 5-ethynyl-2′-deoxyuridine; 
HSVSMC, human saphenous vein–derived smooth muscle cell; IL1α, interleukin-1α; lncRNA, long noncoding RNA; MAPK, mitogen-
activated protein kinase; MOI, multiplicity of infection; ns, not significant; PDGF, platelet-derived growth factor; qRT-PCR, quantitative 
real-time polymerase chain reaction; Si, small interfering; siRNA, small interfering RNA; and UBC, ubiquitin.
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either PDGF or IL1α, whereas conditioned media obtained 
from VSMC stimulated by combination contained signifi-
cantly higher levels of SMILR (4.8±4.5–fold; Figure 5D), 
consistent with the increased intracellular expression of 
SMILR following costimulation of VSMC. Thus, treatment 
with PDGF and IL1α increased intracellular and released 
levels of SMILR.
In addition, we sought to identify if SMILR was encap-
sulated within exosomes or microvesicles. We used both 
ultracentrifugation, to remove cell debris, and an exosome 
isolation kit. Figure XIA and XIB in the online-only Data 
Supplement confirms the presence of microvesicles and 
exosomes by using Nanosight technology and the expres-
sion of the previously described miR-143 within the exo-
somes/microvesicles.28 Our data highlighted the expression 
of SMILR restricted to exosome-free media (Figure IXC in 
the online-only Data Supplement) and the inability to detect 
SMILR expression in the exosome/microvesicle compartment 
using both techniques of isolation. This observation has been 
confirmed by agarose gel electrophoresis (Figure XID in the 
online-only Data Supplement). Primer melting curves are also 
shown in Figure XIE in the online-only Data Supplement. Our 
data confirm that SMILR is secreted into the media and located 
in a nonexosome/microvesicle fraction. This could possibly 
be through interaction with specific membrane channels but 
requires additional experimentation.
In addition, we examined the release of SMILR follow-
ing lentiviral overexpression in IL1- and PDGF-treated cells. 
Lentiviral overexpression resulted in a 10-fold increase in 
SMILR RNA intracellularly. However, only a marginal (not 
significant) increase was observed within conditioned media 
analyzed from infected cells (Figure XIF in the online-only 
Data Supplement). When this media was transferred onto 
additional quiesced cells, no change in proliferation was 
detected (Figure XIG in the online-only Data Supplement). 
This may suggest that the release of SMILR is under a stringent 
control mechanism and simply increasing SMILR expression 
via a lentiviral approach is not sufficient to induce the addi-
tional release of this lncRNA from the cells. In addition, these 
cells were stimulated with IL1α and PDGF, which strongly 
enhances SMILR expression in VSMC. The secretory machin-
ery may have been saturated with the high levels of lncRNA 
within the cytoplasm. This has previously been demonstrated 
with miRNA where high levels of miR, via overexpression 
with miRNA mimics, saturated the exportin-5 pathway of 
endogenous miRNAs with fatal consequences.29,30
Effect of Dicer Substrate siRNA–Mediated 
Knockdown of SMILR on HSVSMC Proliferation
We investigated the function of SMILR using dicer substrate 
siRNA (dsiRNA)–mediated knockdown and 5-ethynyl-2′-
deoxyuridine incorporation. Forty-eight hours after stimula-
tion, IL1α and PDGF treatment induced a 34±15% increase in 
VSMC proliferation in comparison with control (Figure XII 
in the online-only Data Supplement). dsiRNA SMILR caused 
75±24% decrease in SMILR expression in comparison with 
dsi-control (Figure 5E). Following SMILR knockdown with 
dsiRNA, VSMC proliferation was reduced by 56±15% (Figure 
5F). Results were confirmed through the use of a second 
dsiRNA targeting an alternative region of SMILR (Figure 
XIIIA and XIIIB in the online-only Data Supplement). No 
effect on the interferon pathway was observed via assessment 
of the response genes OAS1 and IRF7, which have previously 
been linked to dsiRNA off-target effects31 (Figure XIIIC and 
XIIID in the online-only Data Supplement).
In addition, the effect of SMILR overexpression on VSMC 
proliferation was investigated. VSMCs were infected with 
SMILR lentivirus or empty control for 24 hours before stimu-
lation. Infection at a multiplicity of infection of 25 and 50 
produced a 5.5±3.5– and 11.4±4.7–fold increase in SMILR 
expression in comparison with the empty control, with 
no apparent toxicity effects (Figure 5G). Overexpression 
produced a dose-dependent increase of 1.3±0.3–fold and 
1.66±0.5–fold in VSMC proliferation, respectively (Figure 
5H), confirming the knockdown data.
SMILR Expression Correlates With Other Proximal 
Genes
The expression of lincRNAs can correlate with the expres-
sion of adjacent genes and other RNAs within the genomic 
locale.32 We therefore assessed the expression of genes and 
noncoding RNAs within 5 million base pairs of SMILR, 
from COL14A1 on the forward strand to FERIL6-AS1 on the 
reverse strand (Figure 6A) by using the RNA-seq data set 
(Figure 6B). Upregulation of SMILR was not associated with 
a widespread increase in transcriptional activity within the 
region (Figure 6B). However, similar changes in expression in 
response to VSMC stimulation were observed in 2 proximal 
transcripts (HAS2 and HAS2-AS1). SMILR is located ≈750 
kbp downstream of HAS2 on the same (reverse) strand and 
≈350 kbp from ZHX2 and ≈750 kbp from HAS2-AS1 on the 
opposite strand of chromosome 8 (Figure 6C). The upregula-
tion of HAS2 was accompanied by an increase in HAS1 but 
not HAS3 following dual stimulation (Figure 6D through 6F). 
Interestingly, IL1α and PDGF in combination had no effect 
on HAS3 expression because IL1α and PDGF have opposing 
effects on HAS3 expression (full graph with single stimulation, 
Figure XIIIE and XIIIF in the online-only Data Supplement). 
In addition to SMILR, upregulation of HAS2-AS1 was evident 
following IL1α and PDGF treatment, but not ZHX1 in the 
RNA-seq data (data not shown). This observation was vali-
dated by qRT-PCR (Figure 6G through 6I).
It has been previously shown that lncRNA can modu-
late the expression of nearby protein-coding genes. Thus, the 
expression of proximal genes HAS2, ZHX2, and HAS2-AS1 
was determined following SMILR knockdown. RNA 
interference–mediated knockdown of SMILR significantly 
altered levels of HAS2 mRNA. However, no change in the 
HAS2-AS1 lncRNA or the ZHX2 gene was observed via 
qRT-PCR (Figure 6J through 6L). Results were confirmed 
by using a second siRNA-targeting SMILR (Figure XIIIG 
through XIIII in the online-only Data Supplement). In addi-
tion, no effect on HAS1 or HAS3 expression was observed 
while SMILR siRNA was used, indicating that the effect of 
SMILR knockdown is specific to HAS2 and not all isoforms 
of HAS (Figure 6M and 6N).
In addition, knockdown of HAS2-AS1 greatly reduced 
HAS2 expression with no effect on SMILR expression (Figure 
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Figure 6. SMILR regulates proximal gene HAS2 in chromosome 8. A, Schematic view of the 8q24.1 region showing lncRNAs and protein-
coding genes over the 5 000 000-bp region from Ensemble. B, Regulation of protein-coding and noncoding genes within the selected 
region following IL1α and PDGF treatment; heatmap depicts expression of genes found with RNA-seq in 4 patient samples. C, Dotted 
line marks region containing SMILR lincRNA and closest protein-coding genes HAS2 and ZHX2. D, Expression of proximal gene HAS2 
– modulated in the same manner as SMILR with IL1α and PDGF treatment (n=3). Unpaired t test: ***P<0.001 vs 0.2%. E and F, Additional 
HAS isoforms are differentially modulated by IL1 and PDGF (n=3). Unpaired t test: ***P<0.001 vs 0.2%. G through I, Validation of RNA-
seq data for lncRNAs SMILR and HAS2-AS1 by qRT-PCR (n=3). *P<0.05 and **P<0.01 vs 0.2%, unpaired t test. J, Inhibition of SMILR 
expression via dsiRNA treatment significantly inhibits HAS2 expression determined by qRT-PCR **P<0.01 vs Si control. Unpaired t test 
(n=3). K through N, SMILR inhibition had no effect on proximal genes ZHX2 or HAS2-AS1 nor additional HAS isoforms, HAS1 or HAS3 
(n=3). Unpaired t test. ANOVA indicates analysis of variance; dsiRNA, dicer substrate small interfering RNA; HSVSMC, human saphenous 
vein–derived smooth muscle cell; IL1α, interleukin-1α; lincRNA, intervening long noncoding RNA; lncRNA, long noncoding RNA; PDGF, 
platelet-derived growth factor; qRT-PCR, quantitative real-time polymerase chain reaction; Si, small interfering; and UBC, ubiquitin.
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XIVA and XIVB in the online-only Data Supplement). 
However, the reverse experiment using HAS2 knockdown 
did not affect the expression of HAS2-AS1 or SMILR (Figure 
XIVC in the online-only Data Supplement). Finally, lentiviral-
mediated overexpression did not affect HAS1, HAS2, HAS3, 
or HAS2-AS1 expression (Figure XIVD through XIVG in the 
online-only Data Supplement).
SMILR Expression Is Dysregulated in Unstable 
Human Carotid Plaques 
To investigate the importance of SMILR in human vascular 
pathologies, we assessed levels of SMILR in unstable athero-
sclerotic plaques. We used 2 established inflammatory ([18F]
fluorodeoxyglucose [FDG]) and calcification ([18F]fluoride) 
positron emission tomography radiotracers to define pro-
spectively portions of high-risk plaque33–35 for RNA extrac-
tion. Plaque and relatively healthy adjacent sections of vessel 
were assessed from within individual patients (Table V in 
the online-only Data Supplement for patient characteristics). 
This is of key importance because it permits the assessment 
of noncoding RNA expression from within each micro envi-
ronment (plaque versus nonplaque) from the 1 vessel. In 
comparison with quiescent adjacent tissue, portions of high-
risk plaque showed higher uptake of both [18F]FDG (maxi-
mum tissue-to-background ratio 1.81±0.21 versus 1.31±1.6) 
and [18F]fluoride (maximum tissue-to-background ratio 
2.32±0.52 versus 1.31±0.43) indicating that plaques sub-
jected to RNA analysis had enhanced rates of inflammation 
(Figure 7A through 7G for image examples and Figure 7H 
through 7K for graphs of tracer uptake). Because noncoding 
RNAs have not been assessed in a similar sample set before, 
we first confirmed whether expression of a panel of miRNAs 
associated with atherosclerosis processes were dysregu-
lated.36 As expected, inflammation-associated miRNAs 146a 
and 146b were significantly upregulated in unstable plaques 
in comparison with adjacent quiescent tissue, whereas miR-
29 and miR-204, which are inversely associated with osteo-
blastogenesis and arterial calcification, were downregulated 
in mineralized regions of the atherosclerotic plaque.37,38 
In addition, we also found a downregulation of the miR-
143/145 cluster, which is associated with SMC differen-
tiation and aortic aneurysm formation,39 an event that has 
previously been linked to osteogenic differentiation of SMC 
(Figure 7L). Thus expression of small noncoding RNAs 
(miRs) was associated with positron emission tomography/
computed tomography-defined high-risk plaques. Therefore, 
we used the same cohort of samples to assess SMILR, HAS2, 
and HAS2-AS1 levels. A 3.9±2.3–fold increase in SMILR 
expression was observed in high-risk plaques in compari-
son with adjacent stable regions of the carotid artery (Figure 
7M). Intriguingly, we also observed an increased in HAS2 
(Figure 7N) but not HAS2-AS1 (Figure 7O).
SMILR Is Detectable in Human Plasma and 
Correlates With Inflammatory C-Reactive Protein
Because of the release of SMILR into conditioned media from 
VSMC following stimulation with inflammatory mediators, 
we evaluated whether SMILR was detectable in stored sam-
ples from a cohort of men with varying metabolic dysfunction. 
These samples were ranked in order of the serological param-
eter C-reactive protein (CRP) levels into 3 groups: CRP <2, 
CRP 2 to 5, and CRP >5 mg/L representing broad tertiles 
of CRP. SMILR showed no difference in patients with CRP 
levels below 2 mg/L versus 2 to 5 mg/L. However, a signifi-
cant increase in SMILR was observed when CRP concentra-
tions were >5 mg/ml (0.008±0.006 for CRP <2 mg/L and 
0.046±0.05 for CRP >5 mg/L; Figure 8A). Furthermore, a 
significant positive correlation was seen between SMILR and 
CRP (R2=0.33, P<0.0001; Figure 8B). There was no corre-
lation between SMILR and additional risk factors including 
age (P=0.66), blood pressure (P=0.12), BMI (P=0.14), or 
social deprivation status (P=0.11; Table VI in the online-only 
Data Supplement). Melting curves and gel products of SMILR 
primers in plasma are shown in Figure XV in the online-only 
Data Supplement. Further information regarding the statisti-
cal analysis of SMILR CRP correlation can be found in Figure 
XVI in the online-only Data Supplement.
Discussion
We have shown that stimulation of HSVSMCs with PDGF 
and IL1α increases expression of SMILR. This novel lincRNA 
increases cell proliferation, which may be linked to its ability 
to regulate the proximal gene HAS2. In a clinical setting, we 
found increased expression of SMILR in unstable atheroscle-
rotic plaques suggesting an association with fundamentally 
important vascular pathologies linked to inflammation and 
VSMC proliferation. We also discovered that SMILR can be 
released from cells and is detectable in plasma from patients 
with enhanced inflammation and thus susceptibility to ath-
erosclerosis. These findings support the growing body of evi-
dence that noncoding RNAs can act as mediators to modulate 
disease pathways.
Recent advances in RNA sequencing have demonstrated 
that previously thought genome deserts are in fact perva-
sively transcribed and are populated by lncRNAs. The use 
of paired-end sequencing allowed the accurate alignment 
of reads to the human genome (GRCh37), the 93% align-
ment rate met quality standards for the RNA-seq technique40 
and ensured that our RNA-seq provided a high-quality pro-
file of the HSVSMC transcriptome during quiescent and 
stimulated conditions. Notably, in comparison with control 
cells, protein-coding genes accounted for 3- to 4-fold greater 
abundance than lncRNAs. Our RNA-seq depth of 70 mil-
lion reads was sufficient to identify lncRNAs within VSMC; 
however, it should be noted that greater read depths and the 
use of refined capture-sequencing technique would be ben-
eficial to offer greater annotation of specific areas within the 
genome.
Analysis of the RNA-seq data pinpointed SMILR as an 
IL1α/PDGF–responsive lincRNA located on chromosome 8, 
750 kbp from the closest protein-coding gene, on the same 
strand. This gene, HAS2, encodes an enzyme that synthesizes 
hyaluronic acid (HA), a critical component of the extracel-
lular matrix that accumulates in human restenotic and ath-
erosclerotic lesions.41,42 Our results show that knockdown of 
SMILR reduces HAS2 expression and VSMC proliferation. 
This mechanism of action is supported by a number of studies 
demonstrating that HA can enhance VSMC proliferation and 
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Figure 7. Uptake of [18F]fluoride and [18F]FDG within plaque and normal artery and changes in noncoding RNA expression within carotid 
plaques. Axial images demonstrating unilateral (A, B) or bilateral [18F]fluoride carotid uptake (D, E). C is a multiplanar reformat of B. Axial 
images demonstrating [18F]FDG carotid uptake (F, G). H shows the Siemens Biograph Clinical PET/CT system used for imaging. White 
arrows indicate carotid radioligand uptake. H through K, L, Uptake of tracer: MicroRNA profile of atherosclerotic plaque and paired 
healthy carotid controls (n=6) assessed by qRT-PCR (paired Student t test). Expression of SMILR (M), HAS2 (N), and HAS2-AS1(O) within 
atherosclerotic plaque (n=5). Analyzed via qRT-PCR analysis, ***P<0.001, **P<0.01, and *P<0.05 assessed by paired Student t test. CT, 
computed tomography; [18F]FDG, 18F-fluorodeoxyglucose; PET, positron emission tomography; and qRT-PCR, quantitative real-time 
polymerase chain reaction.
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migration.43 Recent studies using transgenic mice with VSMC-
specific overexpression of HA have found increased suscepti-
bility to atherosclerosis44 and enhanced neointima formation in 
response to cuff injury.45 The ability of SMILR to specifically 
target HAS2 with no effect on HAS1 or HAS3 allows a means 
of specifically altering HAS2 expression, the main HAS iso-
form expressed and functioning in SMC pathology.46
lncRNAs can regulate other RNAs via a number of mech-
anisms,47 including changes in chromatin signatures within 
their locus. For example, the HOTAIR lncRNA is capable of 
repressing transcription in trans across 40 kbp of the HOXD 
locus.48 Thus SMILR may act as an enhancer or scaffold via 
interaction with the promoter region, and potentially other 
transcription factors of HAS2, to regulate expression following 
inflammatory cytokine stimulation. However, further detailed 
coimmunoprecipitation or site-directed mutagenesis studies 
would be required to demonstrate whether SMILR participates 
in transcription factor complexes with NF-κβ or other tran-
scription factors. Previous work has found that HAS2 is regu-
lated by an additional lncRNA, HAS2-AS1.49 Interestingly, our 
RNA-seq data show HAS2-AS1 expression was also upregu-
lated by PDGF treatment alone and in combination with IL1α. 
However, knockdown of SMILR did not alter HAS2-AS1 
expression. lncRNA HAS2-AS1 modulates chromatin struc-
tures around the gene to allow more efficient binding of the 
RNA polymerase 2, and enhanced HAS2 gene expression.49 
This suggests both SMILR and HAS2-AS1 can regulate HAS2 
by independent mechanisms. Interestingly, knockdown of 
HAS2 did not affect either SMILR or HAS2-AS1 expression, 
indicating that the expression of these lncRNAs is not directly 
linked to HAS2 expression.
The composition of extracellular matrix assists in the 
determination of the stability of the atherosclerotic plaques, 
the phenotype of cells within it and the volume of neointima. 
During the progression of atherosclerosis, VSMCs are exposed 
to a plethora of signaling molecules, including inflammatory 
cytokines. Using the clinical gold-standard methods of [18F]
FDG and [18F]fluoride positron emission tomography/com-
puted tomography imaging to identify inflamed, necrotic, 
and mineralizing atherosclerotic plaque,33,34 our results indi-
cate that miRs 29, 143, 145, 146, and 204 are differentially 
expressed in unstable regions of atherosclerotic plaques. 
These miRs have previously been linked to VSMC differentia-
tion, inflammatory cell signaling,50 and VSMC calcification.51 
The strong association and colocalization of SMILR with this 
classical miRNA profile and focal [18F]FDG and [18F]fluoride 
uptake within atherosclerotic plaque suggests that SMILR may 
play a role in atherosclerosis through inflammatory and prolif-
erative pathways. In keeping with our results showing HAS2 
regulation by SMILR, HA content has been shown to reflect 
the progression of atherosclerotic disease and promotes ves-
sel wall thickening.52 Indeed, HA has been implicated in the 
recruitment of inflammatory cells, known to play a prominent 
role in the initiation and progression of atherosclerotic lesion 
to an unstable plaque phenotype.
Our results demonstrate that SMILR is upregulated by a 
combination of PDGF and IL1α in VSMCs but not endothe-
lial cells, suggesting that modulation of SMILR could specifi-
cally alter VSMC proliferation without detrimental effects on 
vessel reendothelialization. If this is the case, it would pro-
vide a suitable candidate to improve antiproliferative therapies 
because current pharmacological agents target cell prolifera-
tion in a non–cell-specific manner, events that can lead to late 
stent thrombosis.53
The ability to identify confidently a plaque, or patient, at 
particular risk of a major adverse cardiovascular event (ie, 
plaque rupture) remains an important goal of cardiovascular 
research. Long RNAs, both mRNA and noncoding RNA, have 
been previously shown to be stable in vivo for up to 3 weeks.54 
As such, the search for prognostic biomarkers has greatly 
increased in recent years. SMILR was expressed in both the 
nucleus and cytoplasm of cells following stimulation and 
was released into the media. It will be important to determine 
whether the cytoplasmic copies induce functional effects, 
such as regulation of gene expression through posttransla-
tional mechanisms or if they are simply being processed for 
release. Dual transcriptional functions of lncRNAs have been 
shown previously,55 but to date no reports of a single lncRNA 
affecting both transcription and translation have been pub-
lished. The release of SMILR could affect function in neigh-
boring cells, particularly in a vascular injury setting where 
phenotypic switching of VSMCs occurs in distinct areas of 
the vessel wall. In support of this theory, it has been shown 
that miR-143/145 can be transferred from VSMC into endo-
thelial cells.56 This transfer produced physiological effects 
Figure 8. SMILR is detectable within plasma samples and 
correlates with patient CRP levels. A, SMILR expression is 
increased in patients with higher CRP levels (n=13 CRP<2; n=13 
CRP2–5; and n=15 CRP>5; *P<0.05, **P<0.01 via 1-way ANOVA). 
B, Correlation between SMILR expression and CRP levels (linear 
regression P<0.0001). CRP indicates C-reactive protein; lncRNA, 
long noncoding RNA; and UBC, ubiquitin.
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within endothelial cells, including modulation of angiogene-
sis. We also found that SMILR could be detected in the plasma 
of patients with higher CRP levels indicative of chronic 
low-grade inflammation. In light of our studies, we propose 
that this release could be attributable to the increased levels 
of SMILR in the diseased vasculature, although delineating 
whether plasma SMILR is simply a by-product of increased 
intracellular levels or is functionally active in disease pathol-
ogy is difficult to definitely demonstrate. However, circulat-
ing levels of miR 143 and 145 are associated with in-stent 
restenosis and, as such, have been proposed as biomarkers.57 
The correlation of SMILR and high CRP further supports its 
expression in low-grade chronic inflammatory settings, and 
proliferative settings, as well. Further large clinical cohorts 
will be required to ascertain if SMILR has prognostic potential 
in inflammatory vascular disease and, if so, whether it pro-
vides enhanced prognostic value over current biomarkers.
Vessel renarrowing after surgical intervention and ath-
erosclerosis remain significant clinical problems, and 
HA/HAS2/SMILR have emerged as key components of these 
pathological processes. Administration of an siRNA targeting 
SMILR could be used to prevent renarrowing after surgical 
intervention for acute coronary syndrome. The use of siRNAs 
has been proven to be effective in phase I clinical trials. Davis 
et al58 recently showed a dose-dependent increase of siRNA 
delivered via nanoparticles and observed a reduction in the 
specific mRNA target. However, we must remain cautious, 
because early clinical trials in the setting of vein graft fail-
ure suggested that antisense oligonucleotides directed against 
E2F (edifoligide) were promising for the treatment of vein 
graft failure and atherosclerosis, but the subsequent phase 3 
Project of Ex Vivo Vein Graft Engineering via Transfection IV 
(PREVENT IV) study yielded largely disappointing results.59 
However, these studies do demonstrate that the surgical set-
ting of coronary artery bypass grafting provides the ideal 
clinical setting to evaluate the clinical efficacy of these targets 
by gene therapy, given that the vein can be transduced ex vivo 
at the time of surgery. Administration of siRNA directly to 
the vessel would obviate the need to administer siRNA sys-
temically and thus reduce the possibility of off-target effects. 
Unfortunately, there are no clear homologues of SMILR in the 
mouse. It would, however, be important to determine whether 
other preclinical models of human vascular disease contain 
SMILR homologues, once this information becomes available.
Taken together, these observations broaden our awareness 
of the complex interplay between lncRNA and protein-cod-
ing genes. The emergence of lncRNAs as regulators of gene 
expression will undoubtedly alter our understanding of the 
complex regulation network of pathological VSMC prolifera-
tion in vascular disease and may provide a means to specifi-
cally target VSMC or identify patients at risk of major adverse 
vascular outcomes.
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CLINICAL PERSPECTIVE
Long noncoding RNAs (lncRNAs) are a relatively new class of discovered RNA molecules that possess important regulatory 
functions. The rapidly expanding catalogue of lncRNAs holds promise that, in the near future, lncRNAs might become rel-
evant to vascular disease clinically as possible biomarkers of cardiovascular events and for targeted treatment of disease. Our 
work indicates that dysregulation of key lncRNAs may have profound implications in regulating vascular smooth muscle cell 
function. In addition, we detected the release of this lncRNA in plasma samples and correlated with inflammatory C-reactive 
protein levels, highlighting new methods and possibilities for improved detection. The emergence of lncRNAs as regulators 
of gene expression and vascular function will undoubtedly alter our understanding of the complex regulation network of cell 
function underpinning clinical vascular disease.
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SUPPLEMENTAL MATERIAL 
Supplemental Methods 
 
Tissue and Cell culture 
Endothelial media supplemented 20% FCS (Life Technologies, Paisley, UK). HSVSMC 
media supplemented with 15% foetal bovine serum (FBS) (PAA laboratories, Yeovil, UK), 2 
mM L-Glutamine (Invitrogen, Paisley, UK) 50 μg/ml penicillin (Invitrogen) and 50 μg/mL 
streptomycin (Invitrogen). All cells were used between passages 3-5. 
 
 
HSVSMC BrdU and EdU Incorporation assay 
HSVSMC proliferation was quantified using a DNA bromodeoxyuride (BrdU) incorporation 
assay (Millipore, Watford, UK), or EdU according to the manufacturer’s instructions. Briefly, 
cells were plated and quiesced in 0.2% FCS media for 48 h prior to stimulation. Cells were 
stimulated with either 10 ng/mL IL1α, 20 ng/mL PDGF or a combination of both for the stated 
times. For BrdU experiments, 6 h after stimulation cells were incubated with BrdU and for 
EdU experiments EdU was added at the point of stimulation for the remaining time to allow 
cell proliferation. BrdU: after removing the culture medium, the cells were fixed followed by 
incubation with anti-BrdU antibody which binds the incorporated DNA. After adding the 
substrate solution, the immune complexes were detected using a plate reader set at dual 
wavelength of 450/550 nm, Victor (Perkin Elmer, Waltham, USA). EdU: following stimulation, 
cellular RNA was extracted as described earlier or fixed in 70% ethanol for EdU FACs 
analysis. EdU incorporation was quantified using Click-it EdU Proliferation assay with an 
Alexa Fluor 594 antibody according to the manufacturer's protocol (Life Technologies). 
 MEKK1 and P38 inhibitor studies 
For inhibitor studies, HSVSMC were plated and quiesced for 48 h. One hour prior to 
stimulation, cells were incubated with either 10, 15 or 20 µM AZD6244 (MEKK1 inhibitor, 
Selleckchem, Suffolk, UK) or 5, 10 or 20 µM P38 (SB 203580). Cells were then maintained 
in either 0.2% media or stimulated with a combination of IL1α and PDGF for 24 h before 
RNA isolation. 
 
 
5’ and 3’ RACE 
5’ 3’ Rapid amplification of cDNA ends 1 was performed to determine the full length transcript 
of SMILR using the SMARTer RACE 5’/3’ Kit (Clontech, Saint-Germain-en-Laye, France) 
according to manufacturer’s instructions. Nested PCR was used to ensure only specific 5’ 
and 3’ products were detected (PCR Primer sequence – Suppl. Table 1). Following cloning 
into supplied cloning vector, products were sequenced. 
 
Fluorescent in situ hybridisation 
Custom RNA-FISH tiled probe sets were generated to all exons of SMILR. RNA FISH 
utilises “branch tree” technology. Briefly, a target specific probe set, containing 40 oligo 
probes, hybridises to the target mRNA as 20 oligo pairs. Each oligo pair forms a required 
platform for assembly of the signal amplification structure (tree) through a series of 
sequential hybridisation steps. Each fully assembled structure, covers a space of 40-50 nt of 
the target RNA, and has the capacity for 400-fold signal amplification. Therefore, a typical 
RNA probe set (containing 20 oligo pairs) has the capacity to generate 8,000-fold signal 
amplification. Due to this technology the company confirms single-molecule RNA sensitivity, 
thus each fluorescent signal corresponds to an individual lncRNA molecule.  
Control SNORD3 and UBC were used as housekeepers to determine spatial location of 
SMILR (Panomics, Affymetrix, California, US). RNA-FISH was performed according to 
manufacturer’s instructions (ViewRNATM cell FISH) with minor modifications for both cell and 
tissue experiments. For cellular analysis, HSVSMC ± IL1α/PDGF were grown on 16-mm 
coverslips to 80% confluency, washed in PBS and fixed in 4% paraformaldehyde 
supplemented with 1% glacial acetic acid. Following detergent QS permeabilisation and 
1:6000 protease digest, coverslips were incubated with a combination of UBC and SMILR 
probe sets or UBC. Probe set buffer was used as a negative control and SNORD3 as 
confirmation of nuclear permeabilisation. Following probe hybridisation, cover slips were 
incubated with branched tree technology pre amplifier for 1 h and amplifier for 30 min. Cover 
slips were finally incubated with fluorescent probes, mounted onto glass slides using Prolong 
gold anti-fade with DAPI mounting medium (Life Technologies).  
 
Image acquisition 
Images acquired on a Zeiss 510 confocal system. At least 5 images were taken per 
condition. Parameters for acquisition and post analysis were identical for all conditions. 
Images were Z stacked to confirm nuclear localisation.  
 
Dicer substrate siRNA (dsiRNA) mediated transfection 
Double stranded dicer substrate siRNA targeting SMILR and Si-control were synthesised 
(Integrated DNA Technologies, Leuven, Belgium). The Si-control does not target any 
sequence in the human, mouse, or rat transcriptomes. Transient transfection was performed 
with Lipofectamine 2000 (Life Technologies). Cells were transfected with either 25 nM Si-
SMILR or Si-Control. Six hours post transfection, cells were quiesced for 48 h and stimulated 
for a further 48 h with 0.2% media containing IL1α/PDGF.  
Lentiviral mediated infection 
Lentiviral vectors were produced by triple transient transfection of HEK293T cells with a 
packaging plasmid (pCMV∆8.74), a plasmid encoding the envelope of vesicular stomatitis 
virus (VSVg) (pMDG) (Plasmid Factory, Bielefeld, Germany) and pLNT/SFFV-MCS plasmid 
employing polyethylenimine (PEI; Sigma-Aldrich, St Louis, USA) as previously described. 
Lentiviral titres were ascertained by TaqMan quantitative real-time PCR (qRT-PCR) using 
the following primer/probe sequences: forward, 5’-TGTGTGCCCGTCTGTTGTGT-3'; 
reverse, 5'- GAGTCCTGCGTCGAGAGAGC-3'; probe, 5'-(FAM)-
CAGTGGCGCCCGAACAGGGA- (TAMRA)-3. SMILR was cloned into the pLNT/SFFV-MCS 
(kind gift from Adrian J. Thrasher, London, UK) plasmid using Platinum taq polymerase, 
according to manufacturer’s instructions, to create pLNT/SFFV-MCS-SMILR. A confluent 
monolayer of smooth muscle cells were plated and infected with a multiplicity of infection of 
either 25 or 50, neither of which induced any form of toxicity in our cells. Following 24 h 
infection, media was changed to 0.2% for a further 48 h. Cells were then stimulated and EdU 
incorporation or SMILR expression investigated as above. 
 
Detection of LncRNA in exosomes secreted from HSVSMC 
SMILR expression in conditioned media utilising both ultracentrifugation and exosome 
isolation kits. RNA extraction of exosome free HSVSMC media was performed using a 
standard volume (15 mL). The conditioned media was centrifuged at 2000 g at 4°C for 10 
min and then at 12000 g for 45 min to remove all cell debris. The supernatant was filtered 
(0.22 µm) followed by ultracentrifugation at 110 000 g, 4°C for 90 min (Optima L-80 XP 
ultracentrifuge Beckman coulter) to obtain microvesicles (MV) and exosomes and exosome 
free media compartments. Additional experiments were performed utilising the Total 
exosome isolation kit (Life technologies) following the manufacturer’s instructions. The 
presence of microvesicles and exosomes was verified using the Nanosight technology  
For exosomes and microvesicles, 700 µL of Qiazol (Qiagen) was added and 3 µL of 
c.elegans total RNA at 25 ng/µL and the RNA was extracted using miRNEasy mini kit 
(Qiagen) as previously described. For the exosome free media compartment, RNA was 
extracted from 2 mL and following the same protocol as describe in the manuscript. SMILR 
relative expression was determined in theses 2 compartments by qRT-PCR.  
 
In Vivo Studies Atherosclerosis Studies: Patients, Imaging and Sampling 
Carotid cohort 
Patients with symptomatic carotid artery stenosis (≥50% by NASCET criteria 2) scheduled to 
undergo carotid endarterectomy were recruited from neurovascular clinics at the Royal 
Infirmary of Edinburgh between January 2013 and April 2014. Exclusion criteria included a 
modified Rankin score of 3, insulin-dependent diabetes mellitus, women of child-bearing age 
not receiving contraception, severe chronic kidney disease (eGFR <30 mL/min/1.73 m2), 
known iodine-based contrast media allergy, prior ipsilateral carotid intervention, prior neck 
irradiation, and inability to provide informed consent. Patients underwent a standard baseline 
clinical assessment including blood sampling (for standard clinical haematological and 
biochemical indices, including C reactive protein, and plasma RNA analysis) before 
undergoing separate [18F]-fluoride and [18F]-fluorodeoxyglucose ([18F]-FDG) positron 
emission tomography 3 combined with computed tomography (CT) scans with the use of a 
hybrid scanner (Biograph mCT, Siemens Medical Systems, Erlangen, Germany). Both of 
these tracers have been used by our group and others for plaque imaging and highlight 
high-risk actively calcifying 4 and inflamed or hypoxic atherosclerotic plaques. 
For [18F]-fluoride imaging, a target dose of 250 MBq was administered intravenously. 
Scanning took place after a 60-min delay. Following an attenuation-correction CT scan (non-
enhanced, low dose 120 kV, 50 mAs) PET imaging was performed in static mode covering 2 
bed positions (15 min each) with the superior bed centered over the carotid bifurcation. 
Following PET acquisition, a CT carotid angiogram was performed without moving the 
patient (Care Dose 4D, 120 kV, 145 mA, rotation time 0.5 s, pitch 0.8). 
[18F]-FDG PET/CT was performed on a separate day. A target dose of 125 MBq was 
administered intravenously and scanning commenced after a 90-min delay. PET/CT 
acquisition was identical to [18F]-Fluoride save for a longer bed time of 20-min and a pre-
scan fast of 6 h. Static images were reconstructed using the Siemens Ultra-HD algorithm 
(time of flight + True X) with corrections applied for attenuation, dead time, scatter, and 
random coincidences.  
PET tracer uptake was quantified using an OsiriX workstation (OsiriX version 3.5.1 64-bit; 
OsiriX Imaging Software, Geneva, Switzerland). PET/CT image data were reviewed for 
evidence of tracer uptake, image quality and registration. The CT angiogram was examined 
to establish plaque presence, location and characteristics. Regions of interest 5 were then 
drawn on three adjacent 3-mm PET slices to incorporate the internal carotid artery plaque. 
Three ROI were then drawn around adjacent healthy portions of carotid artery and the lumen 
of the SVC to derive control values for “normal” arterial uptake and the blood pool 
respectively. Arterial standardized uptake values (SUV) were recorded and also indexed to 
blood pool activity thus giving a target-to-background-ratio (TBR). 
At the time of surgery, plaques were collected immediately following excision and 
photographed. Two-millimeter diameter core biopsy specimens for RNA analysis were taken 
from regions of focally high uptake on PET and from normal tissue at the periphery of the 
endarterectomy specimen. These, along with the main specimen, were immediately frozen 
and placed in an -80°C fridge for subsequent batch analysis. Patient characteristic found in 
Suppl. Table. 5.  
 
 
Assessment of lncRNA in human plasma 
A standard volume of each plasma sample (300 µL) was used to extract RNA. Five volumes 
of QIAzol lysis reagent (Qiagen) was added per extraction and supplemented with spike-in 
RNA controls: 3.5 µL of miRNeasy Serum/Plasma Spike-In Control at 1.6 x 108 copies/µL 
(C. elegans miR-39 miRNA mimic; Qiagen) and 3 µL of c.elegans total RNA at 25 ng/µL. 
Following 5-min incubation at RT, chloroform was added at equal volumes to the starting 
sample. Following centrifugation (15 min; 8000 g; 4°C) the clear upper aqueous phase was 
used to isolate RNA as above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 1: Sybr green primer sequences. Exon spanning lncRNA primers were 
designed to each lncRNA to ensure no genomic DNA was assessed during qRT-PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 2: IL1α stimulation Ingenuity Pathway analysis. Top 10 disease and  
functional pathways predicted to be altered by IPA in HSVSM cells stimulated with IL1α. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 3: PDGF stimulation Ingenuity Pathway analysis. Top 10 disease and 
functional pathways predicted to be altered by IPA in HSVSM cells stimulated with PDGF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 4: IL1α + PDGF stimulation Ingenuity Pathway analysis. Top 10 disease and 
functional pathways predicted to be altered by IPA in HSVSM cells stimulated with IL1α and PDGF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1: Spike-in method of C.elegans total RNA in whole HSVSMC media. (A): 
Dose response effect of C.elegans ama-1 expression. Expression determined by qRT-PCR and 
results displayed as 1/Ct. Number at the top of each histogram corresponds to Ct values. (B): 
Specificity of products analysis by melting curve. (C): Specificity of products analysed using agarose 
gel. The cDNA amplicon size has been resolved by migration on a 2% agarose gel using 100 bp 
ladder. (D): Correlation between quantity spike-in and ama-1 expression. C.elegans ama-1 
expression follow a logarithmic function: y=-1.231ln(x)+30.406 with a coefficient of correlation 
r2=0.9668. (E): Reproducibility of the technique. Following RNA extraction after 75 ng of spike-in total 
C.elegans RNA, ama-1 expression was determined by qRT-PCR and the results have been displayed 
as Ct. 
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Supplemental Figure 2: Assessment of RNA-seq data. (A): Biotype distribution of all transcripts 
identified by RNA-seq analysis generated from HSVSM cells treated with IL1α and PDGF, cutoff at 
FPKM>0.1 (B): IPA analysis of top protein coding genes following IL1α and PDGF treatment. 
 
 
 
 
0.2% vs. IL1 and PDGF 
0.2% IL1α PDGF IL1α + PDGF 
A 
B 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 3: Identification of differentially expressed LncRNAs in HSVSMC treated 
with IL1α and PDGF. Transcripts differentially expressed between 0.2% and stated treatment 
(p<0.01), pie chart indicates the relative percentage, and tables present numbers, of each biotype 
differentially expressed. LncRNAs differentially expressed between 0.2% vs IL1α/PDGF can be 
subdivided based on lncRNA biotype. Groups include intervening lncRNA (lincRNA), antisense, 
overlapping and processed transcripts. 
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Supplemental Figure 4: Heat map of most significantly dysregulated intervening lncRNAs 
across all treatment groups. Heat map shows most significant changes in intervening lncRNA 0.2% 
vs IL1+PDGF treatment. LincRNA cut off using FDR<0.01, FPKM>1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5: Dissociation curves and gel products of PCR reactions indicating 
single PCR products.  (A-H) Dissociation curves and gels for each lncRNA primer set. Primers were 
tested under 0.2% and IL1+PDGFconditions. Each gel also contains lanes containing –ve RT and 
H2O samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
RP11-94a24.1 (v3) RP11-760H22.2 
RP11-709B3.2 RP11-94a24.1 
        RP11-91K9.1 AC018647.3 RP11-94a24.1 (v2) 
UBC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 6: LncRNA tissue and cell specificity analysis. (A): Expression of LncRNAs 
in a healthy tissue panel. Expression determined by qRT-PCR and results displayed as 1/∆CT. (B): 
Expression of lncRNAs in unstimulated HSVSMC, HSVEC or HCAVSMC.  
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Supplemental Figure 7: Validation of additional SMILR primers. (A-C): Assessment of SMILR via 
qRT-PCR expression via 3 independent primer sets. The number on top of graphs represent Ct 
values obtained under 0.2% and dual stimulated conditions.  
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Supplemental Figure 8: Temporal regulation of lncRNA 2 assessed by qRT-PCR. HSVSMC were 
stimulated with IL1α, PDGF of a combination for the stated time points. RNA was extracted and 
expression determined by qRT-PCR. 
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RP1194A24.1LncRNA2  
GCTGCAAACATTGGGATCAGCCGTGACTATCCCATAACATAATATTTCTGATTTCATTCTTTT
CCTTTCTCCTACCAATTTAATCTGCAATCACTTCAAGAGAAGTCTGTTTAAAGGATATTCACA
TTCTG (intron1-11,398) 
TTCACAGAGTTTGAGAGAAACTGTATTCAAGTTGCTGAAACCAAGAAGCTACACTCACGAGT
CTCACCTAAACTCGAATCTGATTTAGATGACATCATCCTGGACTTTGAGTTGATGAAACCTTG
GAGGTCTTGGGAGTAAAGCAAGTGTGATTTGCATATGATGGATATGAATTGTAATGGCCAGA
GCATGGCTGTG (intron 2- 2,269) 
AGATGAAAACTCCCATTTTAGGGAACCAAGACTGAATTCCATAATTTACATGGATGTTTGGAA
GGTGTCTGCAACTTAATCTGTGTTCGTTTCTGAGATGTTGGGCAACTCCTTCTTGGAAGATG
TGGTAATGGTCTCTTCGAAAAGAAAATAATCATCTGAGTTTTGGCCAAAATAGTTGATCGGAT
TACCTATGAAAATGACTCTCACCCAACTACAAGAATGTTATGATGTAGAAACTCTAAATATAT
GAGTAATTAACTATACAACACTCCATCCCCATGTGAAAATCTTTAATCTTTTAAGATACTGAAA
TTTTGTGTATGTCTCATAATTTTCTGTATATGGTCAATGAGTTTTGCCTTAGCCATAAGTGGT
CTGTCTGAAATCTTCTCTATTATTTGTGCATTTTCTTCCTGATGTACCAAGCCTAGTCTGTTTG
TTTTTTCCTAAGAGAAAAGCAGATGATTCAACTGTGTATTTCTCAGTGTTGATATTGTGGTTT
GAGGTATTTCATAATCTTGAGTAAAATCTTGTCATAAAAAAAAAAAAAAAAAAAAA 
Supplemental Figure 9: Visual representation of full SMILR transcript. (A):Grey boxes indicate 
the predicted SMILR sequence obtained from UCSC genome browser (RP11-94A24.1) . Black boxes 
represent additional 316 basepair sequence obtained via 3’ RACE of SMILR transcript. ***P<0.001, ** 
P<0.01 and * P<0.05 vs 0.2% in each time point (1 way ANOVA). (B): Full length sequence of 
lncRNA 2.   
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Supplemental Figure 10: Raw sequencing profiles generated utilising tophat files, constructed 
on integrative genome viewer (IGV). (A): Raw sequencing reads of SMILR under both basal and 
dual stimulated (IL1 + PDGF) conditions n=4. (B): Raw sequencing reads of HAS2 indicating a similar 
expression pattern following stimulation. (C): Raw sequencing reads of SMILR under stimulated 
conditions – expanded (D): Northern analysis of miR146a and SMILR RNA. U6 shown as loading 
control. 
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Supplemental Figure 11: Exosome isolation from HSVSMC conditioned media. (A): Size evaluation using 
the Nanosight of exosomes and MV isolated using the Total exosome isolation kit from 0.2% conditioned media. 
Sizes obtained between 70 and 600 nm. (B): Quantification of miR-143 in exosomes/MV isolated using the Total 
exosome isolation kit from 0.2% conditioned media. (C): SMILR expression analysed by qRT-PCR in 
exosomes/MV and exosomes/MV free media compartment from IL-1α + PDGF conditioned media. (D): Agarose 
gel of qRT-PCR products obtained in C; 1: exosomes/MV compartment, 2: exosomes/MV free media. (E): 
melting curves and gel electrophoresis of SMILR primer set in conditioned media. (F): SMILR expression from 
conditioned media following control lentivirus or SMILR lentivirus infection of cells. (G): Subsequent proliferation 
of quiesced cells following 48h incubation with lentivirus conditioned media.  
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Supplemental Figure 12: Proliferation of HSVSMC 0.2% vs IL1 + PDGF treatment. P<0.05 
students t test.  
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Supplemental Figure 13: (A): Confirmation of siRNA mediated down regulation of SMILR using second 
siRNA targeting a separate sequence of SMILR. (B): Confirmation of knockdown of SMILR using second 
siRNA. Analysed by students t-test ***P<0.001 vs SiControl. (C-D):qRT-PCR analysis of interferon gamma 
associated mRNA OAS1 and IRF7. (E-F): qRT-PCR validation of HAS1 and HAS3 regulation by IL1α and 
PDGF. One way ANOVA *P<0.05. (G-I): Validation of siSMILR using second siRNA targeting different 
section of the lncRNA. 
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Supplemental Figure 14: Effect of HAS2 and HAS2-AS1 knockdown on SMILR expression.  (A): 
Knocdown of HAS2 or HAS2-AS1 both reduced HAS2 expression. (B): Knockdown of neither HAS2 
nor HAS2-AS1 affected SMILR expression levels. (C): Knockdown of HAS2 –AS but not HAS2 
significantly reduced HAS2-AS1levels. (D-F): Overexpression of SMILR did not affect HAS1-HAS3 
nor HAS1-AS1 expression levels.  
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Supplemental Table 5- Baseline Patient Characteristics – Carotid Cohorts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 6- Baseline Patient Characteristics – CRP matched plasma samples. Values 
are represented in mean ± SEM with p values calculated by one-way ANOVA or by Fisher's exact test 
for categorical variables. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 15: Primer validation and quality control in plasma samples.  (A): Melting 
curve for SMILR in plasma. (B): Agarose gel of qPCR product. (C): Water melting curve. 
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  The Pearson correlation: 
 
 
    So r=0.5719, r2=0.327, p<0.001 
  
 
                                               
   If we take out the two outliers (the two highest dCts): 
 
 
 
 
 
         r=0.389, r2=0.151, p=0.014 
 
 
 
 
 
 
Supplemental Figure 16: Statistical analysis of SMILR vs. CRP correlation. (A): Pearson 
correlation of SMILR vs. CRP utilising all data points. R=0.5719, r2=0.327 and P<0.001. (B): Pearson 
correlation of SMILR vs. CRP omitting the 2 highest outlying points. R=0.389, r2=0.151, p=0.014.  
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